SAN DIEGO, Feb. 1 /PRNewswire-FirstCall/ -- CryoCor, Inc. , a medical device company focused on the treatment of cardiac arrhythmias, announced today that it had expanded its Scientific Advisory Board, and added three new medical advisors who specialize in the treatment of atrial fibrillation. Its new medical advisors are Dr. Hugh Calkins, Director of Electrophysiology at Johns Hopkins University, Dr. Mark Josephson, Chief of Cardiology at Beth Israel Deaconess Medical Center, and Dr. Hung-Fat Tse, Professor of Medicine at University of Hong Kong.
“We are thrilled with the addition of our new scientific advisors,” said Dr. Helen Barold, Chief Medical Officer of CryoCor. “These are some of the leading voices in the field of atrial fibrillation ablation, adding to our existing very strong team of scientific advisors. I look forward to consulting with them on ideas to continuously improve and optimize our system for the treatment of atrial fibrillation.”
Dr. Hein Wellens, Chairman of the Department of Cardiology at University Hospital Maastricht, remains as the Chairman of CryoCor’s Scientific Advisory Board, and the other members of the advisory board are Dr. John Camm, Chairman of the Discipline of Cardiac and Vascular Sciences at St. George’s Hospital in London; Dr. Greg Feld, Professor of Medicine at the University of California at San Diego; Dr. Andrew Gage, Professor of Surgery Emeritus at State University of New York at Buffalo; Dr. Helmut Klein, Chief of Cardiology at University Hospitals of Magdeburg; and Dr. Al Waldo, Chief of Electrophysiology at University Hospitals Cleveland.
About CryoCor
CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. CryoCor’s product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, or AF, and atrial flutter, or AFL, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of AF, and has submitted a PMA for the treatment of AFL. For more information please visit CryoCor’s website at http://www.cryocor.com
Forward Looking Statements
The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. These include statements included in this press release related to the anticipated timing of filing a PMA for AF, and the ability to improve and optimize CryoCor’s cryoablation technology. Such statements are only predictions and reflect CryoCor’s expectations and assumptions as of the date of this press release based on currently available clinical, operating, and competitive information. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors, including risks involved with CryoCor’s ability to obtain regulatory approval in the United States for its Cardiac Cryoablation System for use in treating AFL and AF within its anticipated timeframes, if at all; risks associated with CryoCor’s ability to successfully commercialize its Cardiac Cryoablation System in the United States and elsewhere if its Cardiac Cryoablation System is approved for use in the United States; risks associated with CryoCor’s dependence on patents and proprietary rights; risks associated with CryoCor’s protection and enforcement of its patents and proprietary rights; risks associated with the development or availability of competitive products or technologies; and the other risks and uncertainties identified in CryoCor’s filings with the Securities and Exchange Commission. These forward- looking statements speak only as of the date hereof. CryoCor expressly disclaims any intent or obligation to update any of these forward-looking statements.
CryoCor, Inc. The Ruth Group Gregory J. Tibbitts Stephanie Carrington / Nick Laudico Chief Financial Officer (investors) (858) 909-2200 (646) 536-7017 / 7030 gtibbitts@cryocor.comscarrington@theruthgroup.comnlaudico@theruthgroup.com Jason Rando (media) (646) 536-7025 jrando@theruthgroup.com
CryoCor, Inc.
CONTACT: Gregory J. Tibbitts, Chief Financial Officer of CryoCor,+1-858-909-2200; investors, Stephanie Carrington, +1-646-536-7017, orscarrington@theruthgroup.com or Nick Laudico, +1-646-536-7030 ornlaudico@theruthgroup.com or media, Jason Rando, +1-646-536-7025, all ofThe Ruth Group
Web site: http://www.cryocor.com/
